+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID06828796

Early Tacrolimus Use With Post-Transplant Cyclophosphamide in Mismatched Haploidentical Hematopoietic Stem Cell Transplantation

Led by Northside Hospital, Inc. · Updated on 2026-10-14

20

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of starting immunosuppression earlier to reduce Cytokine Release Syndrome CRS in patients undergoing hematopoietic stem cell transplantation. This Phase 2 study focuses on patients receiving a mismatched haploidentical related donor transplant with post-transplant cyclophosphamide. The goal is to improve transplant outcomes by preventing CRS, a serious immune reaction after transplantation. Participants will receive a combination of drugs cyclophosphamide on days 3 and 4 after transplant, tacrolimus starting from day -1 continuing to either day 90 or day 180, and mycophenolate mofetil from day 0 to day 35 post-transplant. This regimen aims to provide early immunosuppression to reduce complications. The study observes a single group receiving this treatment without a comparison group. During the study, participants will be monitored for CRS occurrence and severity within 30 days after transplant, and for safety related to early immunosuppression up to one year. Evaluations include clinical assessments and laboratory tests to track immune response and organ function. The total participation spans up to one year, allowing researchers to gather detailed safety and efficacy data over time.

CONDITIONS

Brief Title

Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide

Research Team

M

Melh Solh, MD

C

Caitlin Guzowski, MBA, MHA, CCRC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here